173 related articles for article (PubMed ID: 37581108)
1. Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
Naipaul R; Marques C; Ng J; Barbour S; Lo C; Hildebrand AM; Siu V; Prasad B; Laurin LP; Wazny LD; Armstrong S; Tran J; Sheffield M; Jauhal A; Hladunewich MA
Can J Kidney Health Dis; 2023; 10():20543581231190227. PubMed ID: 37581108
[TBL] [Abstract][Full Text] [Related]
2. The BC Glomerulonephritis Network: Improving Access and Reducing the Cost of Immunosuppressive Treatments for Glomerular Diseases.
Barbour S; Lo C; Espino-Hernandez G; Gill J; Levin A
Can J Kidney Health Dis; 2018; 5():2054358118759551. PubMed ID: 29581884
[TBL] [Abstract][Full Text] [Related]
3. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
[TBL] [Abstract][Full Text] [Related]
4. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.
Woon DTS; Chandrasekar T; Aaron L; Basappa NS; Chi KN; Conter HJ; Gotto G; Hotte SJ; Malone S; Saad F; Shayegan B; Park-Wyllie L; Hamilton RJ
Can Urol Assoc J; 2018 Oct; 12(10):328-336. PubMed ID: 29688882
[TBL] [Abstract][Full Text] [Related]
5. Provincial Needs Assessment to Determine the Current State of Glomerulonephritis Care in Ontario.
Pang J; D'Antonio C; Heale E; Boll P; Blake P; Evans JM; Hladunewich M
Can J Kidney Health Dis; 2019; 6():2054358119877405. PubMed ID: 31565235
[TBL] [Abstract][Full Text] [Related]
6. Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.
Hasan H; Howard F; Morgan SG; Metzger DL; Lo AC; Goddard K; Gill S; Johnson M
Healthc Policy; 2014 Feb; 9(3):80-96. PubMed ID: 24726076
[TBL] [Abstract][Full Text] [Related]
7. Pharmacists' Scope of Practice: Supports for Canadians with Diabetes.
Mansell K; Edmunds K; Guirguis L
Can J Diabetes; 2017 Dec; 41(6):558-562. PubMed ID: 29037573
[TBL] [Abstract][Full Text] [Related]
8. An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework.
Barbour S; Beaulieu M; Gill J; Djurdjev O; Reich H; Levin A
BMC Nephrol; 2013 Oct; 14():236. PubMed ID: 24168011
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage.
Cadarette SM; Carney G; Baek D; Gunraj N; Paterson JM; Dormuth CR
Osteoporos Int; 2012 Apr; 23(4):1475-80. PubMed ID: 21901476
[TBL] [Abstract][Full Text] [Related]
10. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
Jackson EB; Hotte SJ
Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
[TBL] [Abstract][Full Text] [Related]
11. The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice.
Barbour S; Lo C; Espino-Hernandez G; Sajjadi S; Feehally J; Klarenbach S; Gill J
Nephrol Dial Transplant; 2018 Apr; 33(4):626-634. PubMed ID: 29106654
[TBL] [Abstract][Full Text] [Related]
12. Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
MacPhail C; Snow S
Curr Oncol; 2022 Mar; 29(3):2064-2072. PubMed ID: 35323366
[TBL] [Abstract][Full Text] [Related]
13. Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an example.
Rawson NS
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1072-9. PubMed ID: 19650154
[TBL] [Abstract][Full Text] [Related]
14. A scorecard for osteoporosis in Canada and seven Canadian provinces.
Kendler DL; Adachi JD; Brown JP; Juby AG; Kovacs CS; Duperrouzel C; McTavish RK; Cameron C; Slatkovska L; Burke N
Osteoporos Int; 2021 Jan; 32(1):123-132. PubMed ID: 32712739
[TBL] [Abstract][Full Text] [Related]
15. Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada.
Knowles SR; Lee K; Paterson JM; Shah BR; Mamdani MM; Juurlink DN; Gomes T
Can J Diabetes; 2017 Apr; 41(2):138-142. PubMed ID: 27989494
[TBL] [Abstract][Full Text] [Related]
16. Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies.
Sketris IS; Metge C; Shevchuk Y; Comeau DG; Kephart GC; Blackburn J; MacCara M; Laturnas A
Am J Geriatr Pharmacother; 2004 Mar; 2(1):24-35. PubMed ID: 15555476
[TBL] [Abstract][Full Text] [Related]
17. Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.
Gotfrit J; Shin JJW; Mallick R; Stewart DJ; Wheatley-Price P
Oncologist; 2020 Jan; 25(1):e130-e137. PubMed ID: 31506392
[TBL] [Abstract][Full Text] [Related]
18. Predictive risk modelling of high resource users under different prescription drug coverage policies in Ontario and Manitoba, Canada.
Kornas K; Sarkar J; Fransoo R; Rosella LC
BMC Health Serv Res; 2023 Jul; 23(1):768. PubMed ID: 37468878
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
